AbCellera says ABCL635 Phase 2 trial met primary endpoints on hot flash frequency and severity
AbCellera reported top-line results from the Phase 2 portion of its Phase 1/2 trial of ABCL635, an investigational antibody for hot flashes due to menopause. In the 92-patient, placebo-controlled study, the single 600 mg dose reduced moderate-to-severe hot flash frequency and severity versus placebo at week 4, with no serious adverse events in the ABCL635 group. The results are four-week interim data from a small study, and the company says further data and Phase 3 planning are still ahead.
Key points
- Frequency of moderate-to-severe hot flashes fell 83% from baseline at week 4 on ABCL635 versus 33% on placebo, a placebo-adjusted difference of 50%.
- Severity fell 58% from baseline at week 4 on ABCL635 versus 12% on placebo, a placebo-adjusted difference of 46%.
- No serious adverse events occurred in the ABCL635 group, compared with one serious adverse event in the placebo group.
- Company plans to present additional data at medical conferences later this year and to complete a 12-week follow-up to support dose selection.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 10, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.